With infertility treatment stabilizing in the major markets, pharmaceutical companies are exploring other markets where assisted reproduction techniques (ART) are in growing clinical supply and demand. The need for ART in emerging markets has increased as more centers open, governments develop policies in support of ART, women delay pregnancy and young populations move into reproductive age.

• Assessment of the prevalence of and demand for ART in emerging markets, with a focus on Eastern Europe, Asia and Latin America

  
  

• Analysis of how the cost and level of reimbursement of ART affects demand in the emerging markets

  
  

• Examination of trends in ART and drug treatments in emerging markets, highlighting the drugs and drug classes that are preferred in certain markets

  
  

• Analysis of overall market trends is gleaned from interviews with leading ART practitioners in selected markets

  
  

India is an attractive market beacuse of its highly pronatalist culture, ART-seeking South Asians living abroad and preference for branded products

Recombinant products are posing a great threat to the survival of urinary gonadotrophins in the developed markets; however, in cost-sensitive emerging markets, urinary drugs are expected to maintain a strong presence

Countries in Asia and Latin America are highly cost-sensitive with regard to infertility drug treatment. However, in the presence of strong customer relationship management, ART centers do not always choose to dispense the cheapest drugs

• Ascertain demand for infertility drugs in Eastern Europe, Asia and Latin America

  
  

• Identify treatment trends in ART in emerging markets

  
  

• Identify new market opportunities for established infertility products

  
  

Drivers and trends

What is the demand for infertility drugs in emerging markets?

What socio-economic factors affect demand for ART?

What are the current and future trends in the assisted reproduction procedures available?

How will procedural trends affect the uptake of specific infertility drugs and drug classes?

Pharmaceutical promotions, such as invitations to conferences and educational programs, are attractive incentives for ART centers in many emerging markets.

It is common to have pharmaceutical companies negotiate special prices with ART centers. In some cases, these prices are accompanied by promises to have exclusivity in the center. This practice was cited by one expert as being common in the large ART centers in Brazil and Mexico; however, it appears to be less of a factor in Central and Eastern Europe.

KEY FINDINGS

Four key findings for pharmaceutical companies

India is an attractive market because of its highly pronatalist culture, ART-seeking South Asians living abroad and preference for branded products

Recombinant products are posing a great threat to the survival of urinary gonadotrophins in the developed market; however, in cost-sensitive emerging markets, urinary drugs are expected to maintain a strong presence

Intra-cytoplasmic sperm injection is on the rise in emerging markets, though many experts believe the procedure is being over-used

Countries in Asia and Latin America are highly cost-sensitive with regard to infertility drug treatment. However, in the presence of strong customer relationship management, ART centers do not always choose to dispense the cheapest drugs

DATASETS

Figure 1: Female demographic distribution in select countries

Figure 2: Average cost of IVF, including drugs, in selected countries

Figure 3: IVF results overview in a Czech ART clinic, 1996-2001

Table 1: Proportion of infertile couples able to afford ART: a comparison between Latin American and European countries

Table 2: Number of ART cycles by region and country

Table 3: Reimbursement overview by region and country

Table 4: Marketed infertility products, 2002